Please login to the form below

Not currently logged in
Email:
Password:

Nycomed markets Bonviva drug in Asia

Nycomed has become marketing authorisation holder of osteoporosis treatment Bonviva in key Asia-Pacific countries

Nycomed has completed the transfer of marketing authorisation approval for osteoporosis treatment Bonviva (Ibandronate) in a number of key Asia Pacific markets.

The licensing and supply agreement with Roche covers China, Hong Kong, Malaysia, Australia, New Zealand, Philippines, Singapore, Taiwan and Vietnam, with a future option to commercialise Bonviva in additional Asia Pacific territories.

Under the terms of the deal, Nycomed will hold marketing authorisation holder in all the licensed territories. Bonviva is a bisphosphonate used in the treatment of osteoporosis in post-menopausal women.

Financial details of the agreement were not disclosed.

Guido Oelkers, executive vice-president of commercial operations, said: "The in-licensing of Bonviva from Roche is another important step towards Nycomed's expansion in the Asia Pacific region and demonstrates our growing attraction as a marketing partner for leading companies and brands in these dynamic countries.”

Nycomed recently opened offices in China, South Korea, Indonesia, Malaysia and the Philippines.

15th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Healthcare in a lockdown
Even if patients are getting enough care during the COVID-19 pandemic, are they getting the right care?...
Love in the Time of Coronavirus
Having gone through 4 stages of coping with covid-19: first disbelief, then humour, then creative ways to deal with isolation, and finally the tragic realisation that lives are being lost...
The other side of … multiple sclerosis
No good comes from excluding patients from having a say in their own care. In fact, improving activation (& outcomes) demands it....

Infographics